FDA and U.S. administration advance biotech and drug pricing initiatives

The U.S. Food and Drug Administration (FDA) and biopharmaceutical industry representatives, including the Biotechnology Innovation Organization (BIO), have released the Prescription Drug User Fee Act (PDUFA) VIII commitment letter. This agreement, which guides the FDA’s review process from 2028 to 2032, focuses on stability, transparency, and maturity. The PDUFA system allows the FDA to collect user fees from companies to fund scientific staff, modernize review systems, and monitor drug safety.

Separately, the Trump administration is preparing to announce new agreements with midsize biotechnology companies to lower drug prices. These deals aim to provide discounts on outpatient medicines for state Medicaid programs by aligning U.S. prices with those in other countries. This initiative follows previous voluntary pricing agreements with 17 pharmaceutical companies, which the administration estimates could generate approximately $64.3 billion in federal and state savings over the next decade.